Home » Newsletters » BioWorld

BioWorld

July 8, 1992

View Archived Issues

ANTISENSE DRUG FARING WELL IN SAFETY TRIALS

Ribi To Expand Manufacturing Facility

PPL RAISES $11.6 MILLION IN FINANCING

WAITING PERIOD EXPIRES FOR SCIOS-NOVA MERGER

IMMUNOMEDICS FOUNDER STEPS ASIDE

ELAN STOCK PURCHASE AUTHORIZED

OPPENHEIMER FUNDS INVEST IN PGS

GENE THERAPY FOR CF GETS ORPHAN DESIGNATION

ECOSCIENCE CRADA FOR BIOFUNGICIDE

AMGEN, CELLPRO TEAM FOR CANCER TRIALS

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...